Euratom: Where Are We Now?
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make…
In 2017, Hong Kong fended off perennial competitors, life sciences hubs and innovation powerhouses, Switzerland and Singapore, to rank first in the International Institute for Management Development (IMD)’s World Competitiveness…
The Halal Product Assurance Law, enacted in 2014 and due to be implemented across Indonesia in 2019, will mandate that all food and drink that that enters, is distributed, and…
Long considered maladies of affluent urban populations in mature Western economies, non communicable diseases (NCDs)– such as diabetes, cancer, chronic respiratory and cardiovascular diseases – have been spreading silently and…
PharmaBoardroom’s readers were polled on what they felt was the most disruptive force in the pharmaceutical industry today. Possible answers were big data and digitalization, patient-centricity, economic austerity, and advancements…
In June 2017, PharmaBoardroom hosted an exclusive round table discussion with key players in Algerian healthcare on the role of health economics and patient data in health policy decision making.…
In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs;…
Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe Foundation for Biomedical Research and Innovation (FBRI), discusses the central Japanese city of…
This chart shows how Algeria’s pharmaceuticals and healthcare system has evolved over time; from the creation of the Algerian Central Pharmacy (PCA) back in 1962, all the way to the…
Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within…
According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment…
See our Cookie Privacy Policy Here
